Skip to main content
Premium Trial:

Request an Annual Quote

Ludwig Huber, Daniel Keesman, Martin Hollenhorst, urgen Dormann, Klaus Pohle, Richard Roy, Thure Etzold, Joseph Donahue, William Knight, David Hoffmeister, Eric Winzer, Tim Kish

Premium

Ludwig Huber was named compliance fellow for the life sciences and chemical analysis division of Agilent Technologies. His duties will include helping the company identify and evaluate compliance-related initiatives for pharmaceutical laboratory customers. Huber has been at Agilent and parent Hewlett Packard since 1978.


Daniel Keesman, co-CEO and chief operating officer, and Martin Hollenhorst, co-CEO and chief financial officer, as well as all three members of the supervisory board of Lion BioscienceJurgen Dormann, Klaus Pohle, and Richard Roy — have resigned. Thure Etzold, managing director for Lion Bioscience UK, and Joseph Donahue, chief business officer for Lion Bioscience in North America, have been appointed as co-CEOs. (see brief, p.9)


William Knight has been appointed as the new chief financial officer of Bruker BioSciences, effective Oct. 25. Before joining Bruker, Knight was chief financial officer of Anika Therapeutics, a medical device company based in Woburn, Mass. Prior to that, Knight was chief financial officer for Zykos, NMT Medical, and Zoll Medical.


David Hoffmeister has become CFO and senior vice president of Invitrogen, succeeding Eric Winzer, the Carlsbad, Calif.-based company said this week. He joins the company from McKinsey, where he was a senior partner. Winzer will remain part of the Invitrogen executive team.


Tim Kish, vice president and CFO of Illumina, will resign in the second quarter of 2005 to move back to the East Coast. He will continue to serve in his role as CFO while the San Diego-based firm initiates a search for his successor.

 

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.